SKN | Barclays Turns Cautious on Fresenius Medical Care as Earnings Forecasts Face Significant Downward Revisions

Key Takeaways:

• Barclays downgraded Fresenius Medical Care from Equal Weight to Underweight, reducing its price target from €44.50 to €35 as reimbursement pressures and inflation threaten earnings.
• The bank lowered its 2027 and 2028 adjusted operating profit estimates by approximately 15% to 17%, highlighting a growing gap between its forecasts and management’s growth ambitions.
• Barclays abandoned its discounted cash flow valuation approach in favour of earnings multiples, applying a 45% discount to the healthcare sector to reflect weaker growth prospects.

Barclays has materially revised its assessment of Fresenius Medical Care, adopting a more defensive equity research position as reimbursement uncertainty, limited patient-volume growth and inflation reshape the company’s earnings outlook. The bank downgraded the German dialysis provider from Equal Weight to Underweight and reduced its price target from €44.50 to €35.

The revised target represents a reduction of approximately 21% from the previous valuation and implies 17.3% downside from the November 5 closing price of €42.32. More importantly, the decision reflects a broader reassessment by Barclays of the company’s medium-term profitability, competitive position and ability to deliver sustainable earnings growth.

Barclays Identifies a Structural Gap in Earnings Expectations

A central component of Barclays’ downgrade is its increasingly cautious assessment of Fresenius Medical Care’s operating performance. The bank forecasts adjusted operating profit (EBIT) to decline by an average of 3% annually between 2025 and 2028, contrasting sharply with management’s target of annual growth between 3% and 7%.

Barclays estimates that 2027 adjusted EBIT will reach approximately €1.85 billion, representing a 12% decline at constant currency. Its forecast is 9% below the latest analyst consensus for 2027, while its 2028 estimate is 11% below market expectations.

Reimbursement Risks Prompt Barclays to Cut Forecasts

The bank’s primary concern involves the declining contribution from the U.S. Transitional Drug Add-on Payment Adjustment (TDAPA). Fresenius Medical Care expects this reimbursement mechanism to reduce 2027 EBIT by €300 million to €350 million. Barclays had previously modelled an impact of approximately €210 million, making the revised estimate a significant deterioration in its earnings assumptions.

Barclays also questions the quality of anticipated reimbursement growth. Although the 2027 Medicare reimbursement rate increase for large dialysis organisations is 3.5%, the bank estimates that only 0.4% represents underlying growth. The remaining 3.1% is associated with TDAPA and is expected to decline during 2027.

Consequently, Barclays reduced its 2027 and 2028 adjusted EBIT estimates by approximately 15% to 17%. Its 2027 adjusted earnings-per-share forecast also fell to €3.61 from €4.49, incorporating reimbursement pressures and inflation.

Barclays Changes Its Valuation Framework

Beyond lowering earnings expectations, Barclays has changed how it values Fresenius Medical Care. The bank moved away from a discounted cash flow methodology towards a multiples-based valuation, applying a 45% discount to the healthcare sector.

The revised €35 price target incorporates 10 times expected 2027 earnings and six times expected 2027 enterprise value to EBITDA. Barclays justified the discount by pointing to the company’s relatively weak organic growth, earnings-per-share expansion and operating profit trajectory compared with sector peers.

The bank also expects the company’s 2027 guidance, anticipated in February 2027, to disappoint investors. Its U.S. volume forecast stands at just 0.2% growth in 2027, reflecting patient-referral challenges and stronger competitive performance from DaVita.

What Barclays’ Assessment Means for Portfolio Risk Management

For institutional investors and internationally diversified portfolios, Barclays’ downgrade illustrates the importance of distinguishing between structural healthcare demand and the profitability of individual healthcare operators. Reimbursement arrangements, regulatory decisions and operational execution can materially influence earnings even in essential-service industries.

Looking ahead, the February 2027 guidance, U.S. patient-volume trends and the financial impact of reimbursement changes will remain central to Barclays’ assessment. The bank’s revised forecasts establish a more demanding benchmark for Fresenius Medical Care, while any recovery in patient inflows or improvement in operating execution could challenge its cautious position.

For a confidential discussion on European equity exposure, institutional research assessments and their implications for diversified international portfolios, contact our senior advisory team.